Emerging Technologies

The partnership combines Atropos Health's expertise in real-world evidence generation with Databricks' data intelligence capabilities.  

Molly Gibson, president of future science at Lila Sciences, explains how the company's superintelligence will reshape research across life, chemical and material sciences.

Molly Gibson, president of future science at Lila Sciences, describes the company's scientific superintelligence computer that analyzes various branches of science and creates hypotheses to help researchers find treatments or cure diseases.

Alexandre Momeni, a partner at General Catalyst, describes how the VC firm funds visionary founders building frontier technologies while balancing high-risk bets with responsible innovation and strategic portfolio construction.

Morgan Cheatham, partner and head of healthcare and life sciences at Breyer Capital, provides highlights of the venture capital firm's strategy when funding emerging technologies and the risks associated with backing these innovations.

Jayme Strauss, chief commercial and clinical officer at Precision Neuroscience, joined MobiHealthNews to discuss the company's brain-computer interface aimed at allowing individuals to control digital devices using their thoughts.

Jayme Strauss, Precision Neuroscience's chief clinical and commercial officer, kicks off the Emerging Technologies series, discussing how the company's brain-computer interface, Layer 7, works and what it hopes to accomplish for patients.

Immersive technologies offer powerful new tools for mental healthcare, but their implementation must be grounded in clinical principles and executed with competence.

Marcel Botha, cofounder and CEO of 10XBeta, warns that President Trump's tariffs may jeopardize the quality and safety of medical innovations and hinder patient care.

Indian e-clinic startup CureBay also looks to expand its rural network.